B O O K - American College of Rheumatology

More documents

Recommendations

Info

ACR Poster Session A 281. Innovative Treatment of Experimental Arthritis and Inhibition of Human Osteoclasts Differentiation by Dendrimers. Myriam Hayder 2 , Mary Poupot 1 , Jean-Pierre Majoral 4 , Cédric Olivier Turrin 4 , Anne-Marie Caminade 4 , Alain Cantagrel 3 , Jean-Jacques Fournié 1 , Rémy Poupot 1 and Jean-Luc Davignon 3 , 1 INSERM U563, CPTP, IFR150, Toulouse, France, 2 JE2510, IFR150, Paul Sabatier University, Toulouse, France, 3 JE2510, IFR150, Paul Sabatier University, University Hospital Purpan, Toulouse, France, 4 Laboratoire de Chimie de Coordination, CNRS, Toulouse, France. 282. IRF-1 Reduces TNFα-Induced-IL-18 Bioactivity in Rheumatoid Arthritis Synovial Fibroblasts by Induction of IL-18BPa. Hubert Marotte 1 , Adam J. Pinney 2 , Tatiana Fedorora 2 , Nalin Lalwani 2 , Pei-Suen Tsou 2 , Bradley J. Rabquer 2 and Alisa E. Koch 3 , 1 University of Michigan Medical School, Ann Arbor, MI, 2 University of Michigan Medical School, 3 Veteran’s Administration and University of Michigan. 283. Liposomal Targeting of Glucocorticoids to the Synovial Lining during Experimental Arthritis Inhibits M1 Macrophage Activation in Favour of M2 Differentiation. Wouter Hofkens 2 , Gert Storm 3 , Wim B. Van Den Berg 1 and Peter van Lent 2 , 1 Radboud Univ Nijmegen Med Cntr, Nijmegen, The Netherlands, 2 Radboud University Nijmegen Medical Center, 3 Utrecht University. 284. Nanoparticles of LDE: A Potential Delivery Route for MTX in Sinovial Tissue of Antigen-Induced Arthritis. Suzana B. V. Mello 2 , Eloisa D. O. Bonfá 3 , Claudete J. Valduga 1 , Adriana Bugaralli 1 , Elaine R. Tavarez 1 and Raul Maranhão 1 , 1 Heart Institute (InCor), Faculdade de Medicina da Uiversidade de São Paulo, 2 Reumatology Division, Faculdade de Medicina da Unversidade de São Paulo, São Paulo, Brazil, 3 Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo. 285. Novel Small Molecule Aminopyridizines Inhibit Rat Collagen-Induced Arthritis and Suppress Proinflammatory Cytokine Pathways. Soo-In Choi 2 , Lori D. Klaman 3 , Bruce Connop 3 , Aleksandra Pastrak 3 and Ernest Brahn 1 , 1 Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA, 2 Division of Rheumatology, UCLA School of Medicine and VA Greater Los Angeles Healthcare System, Los Angeles, CA, 3 Transition Therapeutics. 286. PCI-45292, a Novel Btk Inhibitor with Optimized Pharmaceutical Properties, Demonstrates Potent Activities in Mouse Models of Arthritis. Betty Y. Chang 2 , Patricia Thiemann 1 , Nadia Moore 3 , Michelle Francesco 3 , Min Mei Huang 3 , Chitra Mani 3 , Purvi Jejurkar 3 , Danielle Tonev 3 , Wei Chen 3 , Joseph J. Buggy 3 and David J. Loury 3 , 1 Pharmacyclics, 2 Pharmacyclics, Research, Sunnyvale, CA, 3 Pharmacylics. 287. Recognition of IL-23 Dependent and Independent Stages during Autoimmune Collagen-Induced Arthritis. Ferry Cornelissen 2 , Patrick Asmawidjaja 2 , Anne-Marie Mus 2 , Odilia Corneth 2 , Kristine Kikly 1 and Erik Lubberts 2 , 1 Eli Lilly, 2 Erasmus MC, University Medical Center. 288. RO2492, a Phosphoinositide-3-Kinase d Inhibitor, Shows Inhibitory Effects in a Variety of Human Cell Types and Suppresses Collagen-Induced Arthritis in Mice. Cheng Liao 4 , Pei-Yuan Hsu 4 , Shu Jin 2 , Vaishali Patel 2 , Mattew C. Lucas 3 , Yong Nam Kim 3 , Joe Dalpoto 3 , Karim Dabbagh 3 , Emma Masteller 3 , Brian R. Wong 1 , Satwant K. Narula 2 and Julie A. Demartino 3 , 1 Hoffma-La Roche Inc., San Francisco, CA, 2 Hoffma-La Roche Inc., Nutley, NJ, 3 Hoffma-La Roche Inc., 4 Hoffmann-La Roche Inc., Nutley, NJ. 289. Selective Switch Pocket Kinase Inhibitors Suppress Autoimmune Inflammatory Models of Rheumatoid Arthritis. Soo-In Choi 3 , Scott C. Wise 1 , Daniel L. Flynn 1 , Zejin Zhu 3 and Ernest Brahn 2 , 1 Deciphera Pharmaceuticals, 2 Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA, 3 Division of Rheumatology, UCLA School of Medicine and VA Greater Los Angeles Healthcare System, Los Angeles, CA. 290. The Effects of Low Dose Etanercept on Disease Control and Radiographic Progression in Moderate to Severe Rheumatoid Arthritis. Bernd Raffeiner 1 , Costantino Botsios 2 , Paolo Sfriso 2 , Francesca Ometto 2 , Livio Bernardi 2 , Silvano Todesco 2 and Leonardo Punzi 2 , 1 University Hospital of Padova - Rheumatology Unit, Padova, Italy, 2 University Hospital of Padova - Rheumatology Unit (Italy). 291. TNF Inhibitors Induce the Fibrosis in Deep Lining Layers of the Synovium with Degeneration of Synoviocytes in Rheumatoid Arthritis. Shunsei Hirohata 1 , Tetsuya Tomita 2 , Hideki Yoshikawa 3 and Masahisa Kyogoku 4 , 1 Kitasato Univ School of Med, Kanagawa, Japan, 2 Osaka Univ Med School, Suita Osaka, Japan, 3 Osaka Univ Med School, 4 Tohoku Univ School of Med. 292. TNFα-Induced Adipose-Related Protein (TIARP) Regulates Autoimmune Arthritis Via the Suppression of IL-6. Asuka Inoue 1 , Isao Matsumoto 2 , Yoko Tanaka-Watanabe 2 , Kayo Yamamoto 2 , Naoto Umeda 2 , Yuki Tanaka 2 and Takayuki Sumida 3 , 1 Division of Clinical Immunology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba/ JSPS Research Fellow, Tsukuba City, Ibaraki, Japan, 2 University of Tsukuba, 3 University of Tsukuba/ Inst Clin Med, Tsukuba City, Japan. 293. Tyrosin Kinases Are Essential Mediators in the Development of Antigen Induced Arthritis Regulating Formation of Dendritic Cells and Antigen Presentation. Mats I. Dehlin 1 , Sofia Andersson 2 , Malin Erlandsson 2 and Maria Bokarewa 2 , 1 Department of Rheumatology and Inflammation Research, Sahlgrenska University Hospital, University of Göteborg, Gothenburg, Sweden, 2 Department of Rheumatology and Inflammation Research, Sahlgrenska University Hospital, University of Göteborg, Sweden. Rheumatoid Arthritis - Clinical Aspects: Drug Studies, Drug Safety, Disease Activity and Remission, Infections I 294. A Decrease in Neutrophil Counts Following a Single Infusion of Tocilizumab Is Predictive of Low Disease Activity and Remission after 24 Weeks. Jasemine Saech 2 , Kathrin Kuhr 1 , Matthias Laudes 1 , Olaf Schultz 1 , Thomas Rath 1 , Tobias Roehrs 1 and Andrea Rubbert-Roth 1 , 1 University Clinic Cologne, 2 University Clinic of Cologne, Cologne. 295. A Simplified Disease Activity Score (DAS): Validation in the BeSt Trial. Rosanne Koevoets 6 , Yvonne Goekoop-Ruyterman 2 , Desiree M. Van Der Heijde 5 , K. H. Han 7 , H. K. Ronday 1 , T. W. J. Huizinga 6 , P. J. S. M Kerstens 3 , B. A. C. Dijkmans 8 and Cornelia F. Allaart 4 , 1 Haga Hospital, Den Hague, 2 Haga Hospital, Den Hague, The Netherlands, 3 JBI, Amsterdam, 4 Leiden Univ Med Ctr, Leiden, The Netherlands, 5 Leiden University Medical Center, Meerssen, The Netherlands, 6 Leiden University Medical Centre, Leiden, The Netherlands, 7 Maasstad Hospital, Rotterdam, 8 VU Medical Centre, Amsterdam, The Netherlands. 296. Aiming To Reach Remission – Is It Worthwhile? Helga Radner 3 , Josef S. Smolen 1 and Daniel Aletaha 2 , 1 Krankenhaus Lainz, Vienna, Austria, 2 Medical University of Vienna, Vienna, Austria, 3 Medical University Vienna, Vienna, Austria. 166 2010 Program Book
ACR Poster Session A 297. Body Weight and Response to Biologics in RA and Spondyloarthritides. Obesity Reduces the Rate of Remission- Response. The GISEA Registry. Gianfranco Ferraccioli 2 , Francesco Trotta 5 , Leonardo Punzi 11 , Clodoveo Ferri 10 , Piercarlo Sarzi-Puttini 6 , Lisa Maria Bambara 4 , Giovanni Triolo 3 , Roberto Giacomelli 1 , Roberto Gerli 12 , Roberto Gorla 7 , Angelo Marchesoni 13 , Walter Grassi 9 and G. Lapadula 8 , 1 Department of Internal Medicine, University of L’Aquila, L’Aquila, Italy, 2 Division of Rheumatology, UCSC, Rome, Italy, 3 Rheumatology Department, University of Palermo, Palermo, Italy, 4 Rheumatology Department, University of Verona, Verona, Italy, 5 Rheumatology Division, University of Ferrara, Ferrara, Italy, 6 Rheumatology Unit, L Sacco University, Milano, Italy, 7 Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, 8 Rheumatology Unit, University of Bari, Bari, Italy, 9 Rheumatology Unit, University of Marche, Jesi, Italy, 10 Rheumatology Unit, University of Modena, Modena, Italy, 11 Rheumatology Unit, University of Padova, Padova, Italy, 12 Rheumatology Unit, University of Perugia, Perugia, Italy, 13 UOC DH of Rheumatology, G. Pini Orthopaedic Institute, Milano, Italy. 298. Celecoxib, a Selective COX-2 Inhibitor Improved Upper Gastrointestinal (GI) Adverse Lesions in Patients with Rheumatoid Arthritis on Long-Term NSAID Therapy with Endoscopic Evaluation. Shigeyoshi Tsuji 1 , Hirofumi Miyoshi 2 , Tetsuya Tomita 3 , Takanobu Nakase 2 , Masayuki Hamada 2 , Takahiro Oomae 2 , Chikako Tsumoto 2 , Yoshimasa Hirata 2 , Munetaka Iguchi 2 , Shoko Edogawa 2 , Hideo Kawai 2 and Hideki Yoshikawa 4 , 1 Hoshigaoka Kosei-Nenkin Hospital, Hirakata City, Osaka, Japan, 2 Hoshigaoka Kosei-Nenkin Hospital, 3 Osaka Univ Med School, Suita Osaka, Japan, 4 Osaka Univ Med School. 299. Changes in Lipoproteins Associated with MTX, MTX + Etanercept, and Triple DMARD Therapy among Early RA Patients in the TEAR Trial. Jeffrey R. Curtis 6 , Christina Charles- Schoeman 2 , Shuo Yang 4 , Lang Chen 4 , Stacey Cofield 4 , George Howard 4 , Theresa M. McVie 4 , Larry W. Moreland 5 , James R. O’Dell 7 , Harold E. Paulus 1 , Monika Safford 4 and S. Louis Bridges 3 , 1 Encino, CA, 2 UCLA, Santa Monica, CA, 3 Univ of Alabama- Birmingham, Birmingham, AL, 4 Univ of Alabama-Birmingham, 5 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 6 University of Alabama - Brimingham, Birmingham, AL, 7 University of Nebraska Medical Center, Omaha, NE. 300. DAS28 Level at Baseline Best Predicts Which Patients with New Onset Inflammatory Arthritis Will Ultimately Require Biologic Therapy. Vivian P. Bykerk 9 , Gilles Boire 6 , Boulos Haraoui 3 , Carol Hitchon 7 , Diane Ferland 2 , Carter Thorne 4 , Ed C. Keystone 8 , Janet E. Pope 5 and CATCH Investogators 1 , 1 Canada, 2 Hopital Maisonneuve Rosement, Montreal, PQ, Canada, 3 Institut de Rhumatologie de Montreal, Montreal, PQ, Canada, 4 South Lake Regional Health Center, Newmarket, Newmarket, ON, Canada, 5 St Joseph Health Care London, London, ON, Canada, 6 Universite de Sherbrooke, Sherbrooke, PQ, Canada, 7 University of Manitoba, Winnipeg, MB, Canada, 8 University of Toronto, Toronto, ON, Canada, 9 University of Toronto, Boston, MA. 301. Decreased Rate of Remission at 1 Year in Menopaused Women with Early Inflammatory Arthritis: The ESPOIR Cohort Study. Cédric Lukas 2 , Ihsane Hmamouchi 2 , Xavier Le Loet 3 , Bruno Fautrel 1 and Bernard Combe 2 , 1 Department of Rheumatology, La Pitie Salpetriere Hospital, Paris, France, 2 Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 3 Department of Rheumatology, Rouen Hospital, Rouen, France. 302. Demographic, Disease and Treatment Characteristics of the Rheumatoid Arthritis Population Enrolled in the AMORA Study (Applications for Methotrexate Optimization in Rheumatoid Arthritis) in Evaluating the Avise PGSM Test. Prashanth R. Sunkureddi 1 , Judith F. Gendreau 2 , Rong Zablocki 3 and Dawn Navis 3 , 1 Clear Lake Rheumatology, Nassau Bay, TX, 2 Cypress Bioscience, Inc, San Diego, CA, 3 Cypress Bioscience, Inc. 303. Demonstration of the Structural Efficacy of Very Early DMARD Initiation in Early Inflammatory Arthritis in Clinical Practice: Results of a Propensity Analysis in the ESPOIR. Cédric Lukas 3 , Bernard G. Combe 4 , Philippe Ravaud 1 , Jean Sibilia 2 , Robert Landewe 6 and Desiree M. Van Der Heijde 5 , 1 Department of Epidemiology and Biostatistics, Bichat Hospital, Paris, France, 2 Department of Rheumatology, Hautepierre Hospital, Strasbourg, France, 3 Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 4 Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 5 Leiden University Medical Center, Meerssen, The Netherlands, 6 Univ Hosp Maastricht, Maastricht, The Netherlands. 304. Derivation of a Preliminary Administrative Claims-Based Algorithm To Identify Lack of Effectiveness of Rheumatoid Arthritis Medications. Jeffrey R. Curtis 7 , Shuo Yang 4 , John Baddley 1 , Grant W. Cannon 9 , Lang Chen 5 , Elizabeth Delzell 5 , Nivedita M. Patkar 2 , Kenneth G. Saag 8 , Monika Safford 3 , Jasvinder Singh 1 and Ted R. Mikuls 6 , 1 Birmingham VAMC/UAB, 2 Univ of AL at Birmingham, Birmingham, AL, 3 Univ of AL at Birmingham, 4 Univ of Alabama at Birmingham, 5 Univ of Alabama at Birmingham, Birmingham, 6 Univ of Nebraska Med Ctr, Omaha, NE, 7 University of Alabama - Brimingham, Birmingham, AL, 8 University of Alabama-Birmingham, Birmingham, AL, 9 University of Utah, Salt Lake City, UT. 305. Differences in Disease Severity and Response to Biologic Agents in a Racially Diverse US-Based Cohort of Patients with Rheumatoid Arthritis (RA). George A. Karpouzas 2 , Rosalinda Moran 2 , Soha Dolatabadi 1 and Michael Weisman 1 , 1 Cedars Sinai, 2 Harbor-UCLA. 306. Disease Activity in Patients with Early Rheumatoid Arthritis Receiving Stable Conventional DMARDs Significantly Influences the Timing of Achieving a Low Disease State and Remission at 3 Versus 6 Months. Pooneh Akhavan 3 , Vivian P. Bykerk 3 , Ye Sun 4 , J. Hochman 7 , Janet E. Pope 10 , Janet E. Pope 10 , Carol A. Hitchon 11 , Gilles Boire 8 , Boulos Haraoui 2 , Diane S. Ferland 6 , J. Carter Thorne 9 , Deborah A. Weber 5 , Ed C. Keystone 12 and All CATCH Investigators 1 , 1 Canada, 2 Institut de Rhumatologie, Montreal, QC, Canada, 3 Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 4 Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5 Mt Sinai Hosp, Toronto, ON, Canada, 6 Rheumatology, Hopital Maisonneuve, LaSalle, QC, Canada, 7 Rheumatology, University of Toronto, 8 Sherbrooke University, Sherbrooke, QC, Canada, 9 Southlake Regional Health Care, Newmarket, ON, Canada, 10 St Joseph Health Care London, London, ON, Canada, 11 University of Manitoba, Winnipeg, MB, Canada, 12 University of Toronto, Toronto, ON, Canada. 307. Does Sequence Matter When Switching from One Anti–Tumor Necrosis Factor Agent to Another? O. Baser 3 , S. Roy 1 , C. Akin 2 and M. A. Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL, 2 Brigham and Women’s Hospital, Boston, MA, 3 University of Michigan, Ann Arbor, MI. 2010 Program Book 167
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118: ACR Concurrent Abstract Sessions 2:
Page 119 and 120: 3:00 PM 2110. Rheumatologists on th
Page 121 and 122: 2:45 PM 2133. Reasons for Decline i
Page 123 and 124: Session Overview: We are witnessing
Page 125 and 126: Session Overview: Systemic sclerosi
Page 127 and 128: Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130: 5:00 PM 2176. A Role of Autoimmune
Page 131 and 132: 4:30 PM 2198. Association between V
Page 133 and 134: ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136: THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138: • apply these basic statistics to
Page 139 and 140: 9:15 AM The ACR/EULAR Definition of
Page 141 and 142: Immunology, Oslo University Hospita
Page 143 and 144: 9:15 AM 2239. Factors Associated wi
Page 145 and 146: Upon completion of this session, pa
Page 147 and 148: Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150: Ende 4 , 1 Department of Rheumatolo
Page 151 and 152: ACR Poster Session A Cytokines, Med
Page 153 and 154: ACR Poster Session A 51. Associatio
Page 155 and 156: ACR Poster Session A 83. Respirator
Page 157 and 158: ACR Poster Session A 121. Bone Dens
Page 159 and 160: ACR Poster Session A 142. The Intra
Page 161 and 162: ACR Poster Session A 171. Early Pro
Page 163 and 164: ACR Poster Session A Pediatric Rheu
Page 165 and 166: ACR Poster Session A 233. Prevalenc
Page 167: ACR Poster Session A 266. Subtype S
Page 171 and 172: ACR Poster Session A 325. Patient R
Page 173 and 174: ACR Poster Session A 356. Influence
Page 175 and 176: ACR Poster Session A 383. Efficacy
Page 177 and 178: ACR Poster Session A 409. Rituximab
Page 179 and 180: ACR Poster Session A 441. Recombina
Page 181 and 182: ACR Poster Session A 465. Immunoglo
Page 183 and 184: ACR Poster Session A 496. IRF8 Alle
Page 185 and 186: ACR Poster Session A 521. DC-STAMP
Page 187 and 188: ACR Poster Session A 546. Prevalenc
Page 189 and 190: ACR Poster Session A 571. Epidemiol
Page 191 and 192: ACR Poster Session A 599. Validatio
Page 193 and 194: ACR/ARHP Poster Session B Halls B1
Page 195 and 196: ACR Poster Session B 767. Economic
Page 197 and 198: ACR/ARHP Poster Session B 792. The
Page 199 and 200: ACR/ARHP Poster Session B Universit
Page 201 and 202: ACR/ARHP Poster Session B 848. Cell
Page 203 and 204: ACR/ARHP Poster Session B 886. Scre
Page 205 and 206: ACR/ARHP Poster Session B 909. Regu
Page 207 and 208: ACR/ARHP Poster Session B 935. The
Page 209 and 210: ACR/ARHP Poster Session B 967. Frac
Page 211 and 212: ACR Poster Session B 993. Early Exp
Page 213 and 214: ACR/ARHP Poster Session B 1022. Com
Page 215 and 216: ACR/ARHP Poster Session B 1055. Son
Page 217 and 218: ACR Poster Session B 1084. Gene Exp
Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
Page 221 and 222:
ACR Poster Session B hiroshima Memo
Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284:
REF Industry Roundtable-supported S
Page 285 and 286:
REF Industry Roundtable-supported S
Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306:
Cooper, Max D, MD Introduction . .
Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310:
Physical Examination Skills for Imp
Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326:
Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328:
Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330:
Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332:
Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334:
Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336:
Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338:
Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340:
Looney, C 941 Looney, MR 609 Looney
Page 341 and 342:
McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344:
Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346:
Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348:
Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350:
Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352:
1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354:
Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356:
636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358:
Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360:
A α-galactosylceramide 505 A2A kno
Page 361 and 362:
Behcet’s syndrome 1284, 1288, 129
Page 363 and 364:
cost-utility 759, 1539 couples 1324
Page 365 and 366:
fibroblast like synoviocyte 27 fibr
Page 367 and 368:
impact 1063, 1325 inactive disease
Page 369 and 370:
methylation 826, 1253, 1489 methylt
Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
Page 377 and 378:
Abelson, Abby Goulder, MD Education
Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
Page 381 and 382:
ACR Annual Meeting fellowS-in-train
Page 383 and 384:
NOTES 2010 Program Book 381
Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
Page 387 and 388:
Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

Create successful ePaper yourself

Delete template?

Save as template?